Bjorn Johan Niclas Stiernholm

Bjorn Johan Niclas Stiernholm discloses dealings in Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) to SEDI. Over a trading history stretching from 14 July 2011 to 21 August 2017, the count stands at 7 filings.

Every open-market trade on record is a purchase: 6 purchases worth €68k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2017, the count stands at 4 purchases and no sales.

A typical purchase (the median) is worth €12k. None of the 6 purchases we analysed coincided with buying by another insider of the same company within 30 days.

On 21 August 2017 came the latest disclosure, an open-market purchase for €7,913 in Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.). Between a trade and the moment it shows up on SEDI, the median delay is 1 day. That lag is the time during which only the insider knows about the trade. This summary is built from SEDI disclosures alone and does not predict where the share price will go.